Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections – Pipeline Review, H2 2016’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections

The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects

The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc.

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

ContraVir Pharmaceuticals, Inc.

Epiphany Biosciences, Inc.

Foamix Pharmaceuticals Ltd.

GeneOne Life Science, Inc.

GlaxoSmithKline Plc

Green Cross Corporation

Merck & Co., Inc.

N & N Pharmaceuticals Inc.

NAL Pharmaceuticals Ltd.

NanoViricides, Inc.

ReceptoPharm, Inc.

Sinovac Biotech Ltd.

SK Chemicals Co., Ltd.

TSRL, Inc.

XBiotech Inc

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Varicella Zoster (HHV-3) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 10

Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 11

Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 12

Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 14

Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Varicella Zoster (HHV-3) Infections - Products under Development by Companies 19

Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 20

Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 21

Astellas Pharma Inc. 21

Beijing Minhai Biotechnology Co., Ltd 22

Beijing Tiantan Biological Products Co., Ltd. 23

ContraVir Pharmaceuticals, Inc. 24

Epiphany Biosciences, Inc. 25

Foamix Pharmaceuticals Ltd. 26

GeneOne Life Science, Inc. 27

GlaxoSmithKline Plc 28

Green Cross Corporation 29

Merck & Co., Inc. 30

N & N Pharmaceuticals Inc. 31

NAL Pharmaceuticals Ltd. 32

NanoViricides, Inc. 33

ReceptoPharm, Inc. 34

Sinovac Biotech Ltd. 35

SK Chemicals Co., Ltd. 36

TSRL, Inc. 37

XBiotech Inc 38

Zydus Cadila Healthcare Limited 39

Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Combination Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

(measles + mumps + rubella + varicella) vaccine - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

(measles + rubella + varicella) vaccine - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

acyclovir - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

amenamevir - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

chickenpox vaccine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

FV-100 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

GLS-5100 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

GSK-1437173A - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

herpes zoster vaccine - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

HHV-3 vaccine - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

measles + mumps + rubella + varicella vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

MG-1111 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Monoclonal Antibody for Shingles - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

NAL-3221 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

NAL-3223 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

NBP-608 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

NN-001 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

RKP-00156 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

RPI-78M - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

sattabacin - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecule for Shingles - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

TSR-087 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

V-212 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

valomaciclovir stearate - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

varicella zoster vaccine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Varicella Zoster (HHV-3) Infections - Dormant Projects 83

Varicella Zoster (HHV-3) Infections - Discontinued Products 84

Varicella Zoster (HHV-3) Infections - Product Development Milestones 85

Featured News & Press Releases 85

Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM 85

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 86

Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug 87

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 87

Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over 88

Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate 89

Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment 89

Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 90

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 91

Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of

97.2% which does not diminish in the age groups studied 91

Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 92

Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 93

Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 94

Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 94

Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Tables

List of Tables

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016 10

Number of Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Varicella Zoster (HHV-3) Infections – Pipeline by Astellas Pharma Inc., H2 2016 21

Varicella Zoster (HHV-3) Infections – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 22

Varicella Zoster (HHV-3) Infections – Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 23

Varicella Zoster (HHV-3) Infections – Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 24

aricella Zoster (HHV-3) Infections – Pipeline by Epiphany Biosciences, Inc., H2 2016 25

Varicella Zoster (HHV-3) Infections – Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 26

Varicella Zoster (HHV-3) Infections – Pipeline by GeneOne Life Science, Inc., H2 2016 27

Varicella Zoster (HHV-3) Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 28

Varicella Zoster (HHV-3) Infections – Pipeline by Green Cross Corporation, H2 2016 29

Varicella Zoster (HHV-3) Infections – Pipeline by Merck & Co., Inc., H2 2016 30

Varicella Zoster (HHV-3) Infections – Pipeline by N & N Pharmaceuticals Inc., H2 2016 31

Varicella Zoster (HHV-3) Infections – Pipeline by NAL Pharmaceuticals Ltd., H2 2016 32

Varicella Zoster (HHV-3) Infections – Pipeline by NanoViricides, Inc., H2 2016 33

Varicella Zoster (HHV-3) Infections – Pipeline by ReceptoPharm, Inc., H2 2016 34

Varicella Zoster (HHV-3) Infections – Pipeline by Sinovac Biotech Ltd., H2 2016 35

Varicella Zoster (HHV-3) Infections – Pipeline by SK Chemicals Co., Ltd., H2 2016 36

Varicella Zoster (HHV-3) Infections – Pipeline by TSRL, Inc., H2 2016 37

Varicella Zoster (HHV-3) Infections – Pipeline by XBiotech Inc, H2 2016 38

Varicella Zoster (HHV-3) Infections – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 39

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Stage and Target, H2 2016 43

Number of Products by Stage and Mechanism of Action, H2 2016 45

Number of Products by Stage and Route of Administration, H2 2016 47

Number of Products by Stage and Molecule Type, H2 2016 49

Varicella Zoster (HHV-3) Infections – Dormant Projects, H2 2016 83

Varicella Zoster (HHV-3) Infections – Discontinued Products, H2 2016 84

List of Figures

List of Figures

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016 10

Number of Products under Development for Varicella Zoster (HHV-3) Infections – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 40

Assessment by Combination Products, H2 2016 41

Number of Products by Targets, H2 2016 42

Number of Products by Stage and Targets, H2 2016 42

Number of Products by Mechanism of Actions, H2 2016 44

Number of Products by Stage and Mechanism of Actions, H2 2016 44

Number of Products by Routes of Administration, H2 2016 46

Number of Products by Stage and Routes of Administration, H2 2016 46

Number of Products by Molecule Types, H2 2016 48

Number of Products by Stage and Molecule Types, H2 2016 48

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports